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Background: Although gastric cancer screening is common among countries with a high prevalence of gastric cancer, there is
little data to support the effectiveness of this screening. This study was designed to determine the differences in stage at
diagnosis of gastric cancer according to the screening history and screening method (upper gastrointestinal series (UGIS) vs
endoscopy).
Methods: The study population was derived from the National Cancer Screening Programme (NCSP), a nationwide organised
screening programme in Korea. The study cohort consisted of 19 168 gastric cancer patients who had been diagnosed in 2007 and
who were invited to undergo gastric cancer screening via the NCSP between 2002 and 2007.
Results: Compared with never-screened patients, the odds ratios for being diagnosed with localised gastric cancer in endoscopy-
screened patients and UGIS-screened patients were 2.10 (95% CI¼ 1.90–2.33) and 1.24 (95% CI¼ 1.13–1.36), respectively.
Conclusions: Screening by endoscopy was more strongly associated with a diagnosis of localised stage gastric cancer compared
with screening by UGIS.
Although, the incidence of gastric cancer is declining worldwide,
gastric cancer remains the third most common cause of cancer
death (Ferlay et al, 2013). Survival from gastric cancer remains low
in the Western world, with reported 5-year survival rates of 10–
30% (Karim-Kos et al, 2008), in contrast to survival rates in Asia of
69% (Nashimoto et al, 2013; Jung et al, 2014). The higher survival
rate from gastric cancer is partly attributed to the availability of
screening programmes. In countries with a high prevalence of
gastric cancer, specifically in Japan and Korea, gastric cancer
screening is commonly conducted.
Japan has been conducting mass gastric cancer screening using
photofluorography (via indirect upper gastrointestinal series
(UGIS)) since 1960 and has achieved a remarkable reduction in
mortality rates and consequently higher cure rates (Fukao et al,
1995; Mizoue et al, 2003; Miyamoto et al, 2007). In recent years,
the main method used for opportunistic screening in Asia has been
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endoscopy (Leung et al, 2008). In Korea, a nationwide gastric
cancer screening programme was started in 1999 as part of the
National Cancer Screening Programme (NCSP). The NCSP
provides biennial gastric cancer screening for men and women
aged 40 or over, by either UGIS or endoscopy (Kim et al., 2011).
Recently, a case-control study and a cohort study in Japan reported
a 30–65% reduction in gastric cancer mortality when screening was
undertaken via endoscopy (Hosokawa et al, 2008; Hamashima
et al, 2013). However, there is a lack of agreement about which
method is most effective in the general population.
Although randomised controlled trials represent the most
reliable method for evaluating the impact of screening on cancer
mortality reduction, such intervention studies are not feasible in
most countries because gastric screening is already being widely
conducted. Thus, no randomised control trial addressing the
efficacy of gastric cancer screening on mortality reduction has been
published. Furthermore, obtaining accurate estimates of reductions
in mortality requires long-term follow-up of large populations.
Therefore, stage at diagnosis was used as an intermediate outcome
measure, as it is the most powerful predictor of patient survival. To
date, no study has reported differences in stage at diagnosis of
gastric cancer among gastric cancer patients who have undergone
endoscopy screening and those who have undergone UGIS
screening. Thus, the primary aim of this study was to determine
whether differences in stage at diagnosis of gastric cancer exist
among gastric cancer patients who participated in the NCSP (ever
screened) and those who have no screening history (never
screened). Furthermore, this study aimed to evaluate whether
there is an association between stage at diagnosis of gastric cancer
and screening method (UGIS vs endoscopy).
MATERIALS AND METHODS
The study cohort consisted of patients aged 40 years or over with a
diagnosis of gastric cancer reported in the Korean Central Cancer
Registry (KCCR) in 2007. Among the 25 915 gastric cancer patients
identified, 19 168 had been invited to gastric cancer screening
through the NCSP in 2002–2007 and were included in the final
analysis. In the NCSP, all men and women aged 40 or over (no
upper age limit) receive an invitation letter from the National
Health Insurance Service (NHIS) at the beginning of the year.
Individuals invited to participate in the NCSP for gastric cancer
can choose to undergo either UGIS or endoscopy screening at a
clinic or hospital designated as a gastric cancer screening unit by
the NHIS. Participants with a positive screening result on UGIS are
offered a follow-up endoscopy test within the framework of the
NCSP. The screening units report all screening results to the
NHIS through a web-based database maintained by the NHIS
(Kim et al, 2011).
Using the NCSP database, gastric cancer patients were classified
by screening history in 2002–2007 (9191 never screened and 9977
ever screened). Never-screened gastric cancer patients were
matched with ever-screened gastric cancer patients according to
age, gender, and socioeconomic status. If there was no age match
for a given patient, we considered those within the range of 2 years
above or below the target age. A total of 8044 never-screened
gastric cancer patients were matched to the same number of ever-
screened gastric cancer patients. We obtained written informed
consent form participants who underwent screening for the
collection of their screening results and health data recorded
during the screening process. This retrospective study was
approved by the institutional review board of the National Cancer
Center, Korea.
Information on stage at gastric cancer diagnosis, anatomic site,
and histological classification was obtained from the KCCR.
Tumour stage was recorded as localised, regional, distant, or
unknown, in accordance with the categories used in the
Surveillance, Epidemiology, and End Results (SEER) Cancer
Statistics Review of the National Cancer Institute (Young et al,
2001). Localised neoplasms are confined entirely to the stomach
and lack serosal involvement; intramucosal tumours are also
classified as localised cancer. Regional cancers comprise tumours
limited to the gastric wall with regional lymph node involvement
or tumours with extension to nearby viscera. Distant neoplasms
exhibit distant extension or metastases in the viscera or distant
lymph nodes. Unknown stage refers to neoplasms lacking sufficient
or unavailable information with which to assign a category.
Information on socioeconomic status and screening history was
extracted from the NCSP database. Gastric cancer patients were
categorised by screening method (UGIS, endoscopy, and never
screened), screening frequency (number of screenings received
between 2002 and 2007: once, twice, three times or more, or never
screened), and interval between date of gastric cancer diagnosis
and the preceding screening date. The demographic characteristics
of case and controls were compared using w2-tests.
Conditional logistic regression was performed either including
or excluding ‘unknown stage’ to calculate odds ratios (ORs) and
95% confidence intervals (CIs) for being diagnosed with localised
gastric cancer. We conducted subgroup analyses stratified by age,
sex, socioeconomic status, screening method, screening frequency,
and time interval since screening. The SAS software package (ver.
9.1; SAS Institute Inc., Cary, NC, USA) was used for all statistical
calculations.
RESULTS
Baseline demographic and tumour characteristics of ever-screened
and never-screened gastric cancer patients are shown in Table 1.
Noncardia gastric cancer, intestinal histological subtypes, and
localised gastric cancer were significantly more frequent in ever-
screened patients compared with never-screened patients
(Po0.001).
Figure 1 shows the distribution of stage at gastric cancer
diagnosis. Localised gastric cancer was most frequently noted in
both never-screened and ever-screened patients; however, between
these two groups, localised cancer were more frequently recorded
in ever-screened patients (Figure 1A). In addition, localised cancers
were most frequent in patients who had undergone endoscopy,
compared with patients who had undergone UGIS or never-
screened patients (Figure 1B).
We evaluated the odds of being diagnosed with localised gastric
cancer vs regional, distant, or unknown-stage gastric cancer in each
subgroup according to screening history (Table 2). Overall, ever-
screened patients were statistically significantly more likely to be
diagnosed with localised gastric cancer (adjusted OR (aOR)¼ 1.71;
95% CI¼ 1.60–1.82). This odds increased when ‘unknown stage’
was removed from the analysis (aOR¼ 1.81; 95% CI¼ 1.68–1.96).
Compared with the never-screened patients, patients who had
undergone screening by endoscopy were also more likely to be
diagnosed with localised gastric cancer (aOR¼ 2.10; 95%
CI¼ 1.90–2.33). Although the risk of localised gastric cancer
increased by 1.24 among patients screened by UGIS, compared
with never-screened patients, the OR was much lower than that for
patients screened by endoscopy. Further, patients who had
undergone screening by endoscopy were 1.71 times (95%
CI¼ 1.55–1.89) more likely to be diagnosed with localised gastric
cancer compared with UGIS-screened patients (not shown in
table). The OR for being diagnosed with localised gastric cancer
was highest among patients who had a screening frequency of three
times or more. Compared with never-screened patients, the OR for
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being diagnosed with localised gastric cancer was the highest
within 12 months of diagnosis (aOR¼ 1.82; 95% CI¼ 1.69–1.96),
after which the ORs tended to decrease with an increasing time
interval.
DISCUSSION
In the current study, we noted a large and highly significant
increase in the diagnosis of localised gastric cancer, and a
corresponding decrease in the diagnosis of regional and distal
gastric cancer, among ever-screened patients relative to never-
screened patients. As well, endoscopy was more strongly associated
with an earlier stage of gastric cancer at diagnosis than UGIS.
As stage at diagnosis of gastric cancer is well correlated with
survival rate, (Jung et al, 2013) in the current study, we assumed
that early detection of gastric cancer by screening may increase
patient survival. A previous study conducted on patients with
cardia adenocarcinoma found that 49% of gastric cancer patients
who underwent previous endoscopy presented with in situ or
localised gastric cancer, compared with 27% of those who did not
have a previous endoscopy (Cooper et al, 2002). These findings are
compatible with our study and are consistent with the notion that
screening by endoscopy leads to earlier diagnosis of gastric cancer.
In the current study, patients screened by endoscopy were 2.1
times more likely to be diagnosed with localised gastric cancer.
Although the odds of having localised gastric cancer also increased
by 1.24 among patients screened by UGIS, the odds were much
lower than that for patients screened by endoscopy. Thus, we could
suggest that endoscopy is more likely to detect localised gastric
cancer than UGIS.
We also evaluated who might benefit from gastric cancer
screening according to time interval since last screening.
Compared with never-screened patients, the ORs were highest
for those screened within 12 months of diagnosis and tended to
decrease with an increasing time interval. A few Asian studies have
reported that screening by endoscopy every 2 years increases the
detection rate of early-stage gastric cancer (Mori et al, 2001; Nam
et al, 2009). A cohort study conducted in Korea also reported that
the risk of higher cancer stage at diagnosis increased by 23% per
increase in 1 year interval length (OR¼ 1.23; 95% CI¼ 1.19–1.28),
and endoscopy intervals of 3 years or less showed similar benefits
(Nam et al, 2012).
This study had several limitations. First, in order to evaluate the
effects of cancer screening, study subjects should be asymptomatic;
however, it was not possible to exclude symptomatic individuals in
the NCSP database. As symptomatic individuals are more likely to
be diagnosed with advanced-stage gastric cancer, the proportion of
early-stage diagnoses in the ever-screened group might be under-
estimated. Second, screening history outside of the NCSP was
unclear. Screening history was identified based on the participant
lists for gastric cancer screening from 2002 to 2007 through the
NCSP database. However, opportunistic screening for gastric
cancer using endoscopy is often performed in Korea. Thus, among
the never-screened group, there may have been some individuals
who had undergone opportunistic gastric cancer screening.
Table 1. Demographic and tumour characteristics of ever-
screened and never-screened gastric cancer patients,
National Cancer Screening Programme
Never
(n¼8044)
Ever
(n¼8044)
Characteristics n (%) n (%) P-value
Gender 1.000
Male 5685 (70.7) 5685 (70.7)
Female 2359 (29.3) 2359 (29.3)
Age at diagnosis, years 0.854
p49 839 (10.4) 807 (10.3)
50–59 2059 (25.6) 2080 (25.9)
60–69 2495 (31.0) 2490 (31.0)
70p 2651 (33.0) 2667 (33.2)
Socioeconomic status 1.000
NHI with premium under 50% 3729 (46.4) 3729 (46.4)
NHI with premium over 50% 3823 (47.5) 3823 (47.5)
MAP recipients 492 (6.1) 492 (6.1)
Anatomic site o0.001
Noncardia 5852 (72.8) 6150 (76.5)
Cardia 320 (4.0) 331 (4.1)
Overlapping 722 (9.0) 593 (7.4)
Unspecified 1150 (14.3) 970 (12.1)
Histological subtype o0.001
Intestinal 3941 (49.0) 4446 (55.3)
Diffuse 1336 (16.6) 1294 (16.1)
Other or unspecified 2767 (34.4) 2304 (28.6)
Stagea o0.001
Localised 3264 (40.6) 4326 (53.8)
Regional 2372 (29.5) 1905 (23.7)
Distant 1134 (14.1) 660 (8.2)
Unknown 1274 (15.8) 1153 (14.3)
Abbreviations: MAP¼medical aids programme; NHI¼ national health insurance; SEER¼
Surveillance, Epidemiology, and End Results; UGIS¼upper gastrointestinal series.
aStage definitions adapted from the SEER Cancer Statistics Review were applied: localised,
a neoplasm confined entirely to the stomach without serosal involvement; regional, a
neoplasm that extends beyond the limits of the stomach and invades the surrounding
tissue; distant, a neoplasm that spreads to parts of the body remote from the primary
tumour; and unknown, a neoplasm with insufficient or unavailable information to assign a
stage.
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Figure 1. (A) Distribution of stage at gastric cancer diagnosis in patients
according to history of gastric cancer screening via the National Cancer
Screening Programme. (B) Distribution of gastric cancer stages in
patients by screening method. aThe following stage definitions were
applied (adapted from the SEER Cancer Statistics Review): localised,
a neoplasm confined entirely to the stomach without serosal
involvement; regional, a neoplasm that extends beyond the limits of
the stomach and invades the surrounding tissue; distant, a neoplasm
that spreads to parts of the body remote from the primary tumour; and
unknown, a neoplasm with insufficient or unavailable information to
assign a stage.
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Nevertheless, this factor might have led to the underestimation of
the magnitude of the observed screening effect. Finally, gastric
cancer screening efficacy cannot be directly estimated by cancer
stage, as there might be a gap related to lead-time bias and length
bias between cancer stage and mortality. In this study, stage at
diagnosis was used as an intermediate outcome measure to predict
survival. However, lead-time bias occurs in such a way that the
survival of screen-detected cases appears to be lengthened,
whereas, in actuality, the screening simply advances the date of
the diagnosis, extending the period between diagnosis and death,
without actual prolongation of life. Also, a higher proportion of
localised gastric cancers in the screening group might be associated
with the tendency of screening to detect slow-growing lesions with
better prognosis and to miss fast-growing lesions with poorer
survival. Thus, the efficacy of any screening should be evaluated in
terms of whether mortality from cancer is reduced in the screened
population, and therefore, further study is needed to determine
whether gastric cancer screening is effective in reducing mortality.
Despite of these limitations, this study suggests the following
implications. First, gastric cancer screening using endoscopy was
shown to be associated with an earlier stage at gastric cancer
diagnosis in patients aged 40 years or over. Also, our data suggest
that endoscopy is more likely to detect localised gastric cancer
compared with UGIS. Although the data presented here are
preliminary, our intermediate outcomes indicate that, in Korea,
the introduction of gastric cancer screening by endoscopy
in the average-risk population appears to perform better than
screening by UGIS. However, data on the impact of endoscopy
screening programmes on gastric cancer mortality are limited.
Thus, further study is needed to determine whether endoscopy
screening is more effective than radiography screening in
reducing mortality.
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